20/20 BIOLABS, INC. (AIDX) Current Ratio
- Current ratio · latest quarter: Value 1.99×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.99× | Current assets / current liabilities. $5.08M ÷ $2.55M ≈ 1.99× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 5.08M USD | Assets, Current |
| Current obligations | 2.55M USD | Liabilities, Current |
| Cash and equivalents | 4.55M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 291.49K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 111.04K USD | Inventory, Net |
| Payables | 1.03M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.08M | $2.55M | $4.55M | (m) | $291.49K | $111.04K | $1.03M | (m) | 1.99× |
| 2026-03-31 | $4.70M | $2.58M | $4.22M | (m) | $201.48K | $104.52K | $980.49K | (m) | 1.82× |
| 2025-12-31 | $1.47M | $2.46M | $1.03M | (m) | $199.95K | $116.22K | $868.54K | (m) | 0.60× |
| 2024-12-31 | $2.03M | $1.36M | $1.78M | (m) | $135.27K | $47.16K | $372.30K | (m) | 1.50× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGENOMICS INC (NEO) | United States | $2.514B | -35.96 |